Register for our free email digests:
Latest From Athenex Inc.
Nineteen biopharma firms went public in the US during the first half of 2017, but as the number of IPOs increased, the average return on first-time offerings decreased, raising a key question: can this pace of first-time offerings continue in the second half?
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.
How FDA, health care providers, and Pfizer and other drug makers are responding to a shortage of emergency medicines from the fragile, overstressed US sterile injectables sector.
Athenex and Immuron launched IPOs in the US, but June has otherwise been a pretty quiet month for new biopharma financings – so far. The largest VC round so far this month is Checkmate's $27m Series B and the biggest public offering was conducted by CTI BioPharma, raising $45m.
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Equipment & Devices
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Spotlight Surgical Inc.
- North America
- Parent & Subsidiaries
- Invuity Inc.
- Senior Management
Philip Sawyer, Pres. & CEO
James Mackaness, CFO
Alex Vayser, CTO
Paul Davison, VP, R&D
Doug Heigel, Vp, Ops
Joe Guido, VP, Commercial Marketing & BD
Steve Annen , VP, Product Management & Strategy
- Contact Info
Phone: (415) 655-2100
444 De Haro Street
San Francisco, CA 94107
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.